Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
Frequently Asked Questions
What is Market Cap of Aevi Genomic Medicine Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Aevi Genomic Medicine Inc market cap is N/A.
What is the 52-week high for Aevi Genomic Medicine Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aevi Genomic Medicine Inc 52 week high is N/A as of October 03, 2025.
What is the 52-week low for Aevi Genomic Medicine Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aevi Genomic Medicine Inc 52 week low is N/A as of October 03, 2025.
What was Aevi Genomic Medicine Inc stock price yesterday?
Aevi Genomic Medicine Inc stock price yesterday was $0.1659.
What is the PE ratio of Aevi Genomic Medicine Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Aevi Genomic Medicine Inc’s P/E ratio is None.
What is the Price-to-Book ratio of Aevi Genomic Medicine Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Aevi Genomic Medicine Inc P/B ratio is None.
What is Aevi Genomic Medicine Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Aevi Genomic Medicine Inc's EBITDA is -0.49.
What is the 50-day moving average of Aevi Genomic Medicine Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aevi Genomic Medicine Inc 50-day moving average is N/A.
How many employess does Aevi Genomic Medicine Inc has?
